abstract |
Compounds of formula (I); wherein R 1 is H or NHZ; R 2 is optionally substituted aryl or heteroaryl attached via a carbon atom; R 3 is H; optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 C 7 cycloalkyl, halogen; OH or OR, or R 4 is H, optionally substituted C 1 -C 6 alkyl, C 3 C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl, R 5 is H or optionally substituted C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, or C 3 -C 7 cycloalkyl; or R 4 and R 5 together form a 5 or 6-membered heterocyclic ring; and R 10 is optionally substituted C 1 -C 6 alkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease. |